The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Slides:

Advertisements

Similar presentations

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Advertisements

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Timothy S.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma Baldeep Wirk, Timothy S. Fenske,

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis Sonali.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma Robert F. Cornell, Anita D'Souza, Adetola.

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia Karen K. Ballen, Ann E. Woolfrey, Xiaochun.

Yoshihiro Inamoto, Mary E. D

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.

Sabina Kersting, Leo F. Verdonck

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR Gregory.

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma Marcel P. Devetten,

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Ayman.

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age Lynda M. Vrooman,

Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative.

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Manish Sharma, Mei-Jie Zhang, Xiaobo Zhong, Muneer H

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease.

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse.

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure Mouhab Ayas, Mary Eapen, Jennifer Le-Rademacher,

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation Shaji Kumar, Waleska S. Pérez, Mei-Jie.

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia William A. Wood,

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗ Theresa Hahn, Philip L. McCarthy,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Salvage Second Hematopoietic Cell Transplantation in Myeloma

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen Alvaro Urbano-Ispizua, Steven Z. Pavletic, Mary E. Flowers, John P. Klein, Mei-Jie Zhang, Jeanette Carreras, Silvia Montoto, Miguel- Angel Perales, Mahmoud D. Aljurf, Görgün Akpek, Christopher N. Bredeson, Luciano J. Costa, Christopher Dandoy, César O. Freytes, Henry C. Fung, Robert Peter Gale, John Gibson, Mehdi Hamadani, Robert J. Hayashi, Yoshihiro Inamoto, David J. Inwards, Hillard M. Lazarus, David G. Maloney, Rodrigo Martino, Reinhold Munker, Taiga Nishihori, Richard F. Olsson, David A. Rizzieri, Ran Reshef, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Sonali M. Smith, Gérard Socié, Baldeep Wirk, Lolie C. Yu, Wael Saber Biology of Blood and Marrow Transplantation Volume 21, Issue 10, Pages 1746-1753 (October 2015) DOI: 10.1016/j.bbmt.2015.05.010 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Overall survival of the different lymphoma subtypes, in the overall group. Biology of Blood and Marrow Transplantation 2015 21, 1746-1753DOI: (10.1016/j.bbmt.2015.05.010) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Progression-free survival of the different lymphoma subtypes, in the overall group. Biology of Blood and Marrow Transplantation 2015 21, 1746-1753DOI: (10.1016/j.bbmt.2015.05.010) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of relapse per lymphoma subtype in the overall group (A), in myeloablative conditioning (B), and in reduced-intensity conditioning (C). Biology of Blood and Marrow Transplantation 2015 21, 1746-1753DOI: (10.1016/j.bbmt.2015.05.010) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Landmark analysis at 180 days after RIC allo-HCT showing the cumulative incidence of relapse in patients who had: (1) no acute GVHD, no chronic GVHD (AG-N/CG-N); (2) acute GVHD, no chronic GVHD (AG-Y/CG-N); (3) no acute GVHD, chronic GVHD (AG-N/CG-Y); and (4) both acute GVHD and chronic GVHD (AG-Y/CG-Y) in (left) mantle cell lymphoma and in (right) follicular lymphoma. Biology of Blood and Marrow Transplantation 2015 21, 1746-1753DOI: (10.1016/j.bbmt.2015.05.010) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions